Morgan Stanley
PMN icon

Morgan Stanley’s ProMIS Neurosciences PMN Stock Holding History

Morgan Stanley’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.5K Buy
+7,559
New +$82.1K ﹤0.01% 6256
2023
Q3 		– Sell
-72
Closed -$7.01K – 7687
2023
Q2 		$7.01K Sell
72
-28
-28% -$3.72K ﹤0.01% 6914
2023
Q1 		$11.9K Sell
100
-12
-11% -$1.47K ﹤0.01% 6824
2022
Q4 		$12.2K Sell
112
-125
-53% -$17.5K ﹤0.01% 6870
2022
Q3 		$36K Buy
+237
New +$34.9K ﹤0.01% 6555

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Morgan Stanley's PMN Position: Q2 2026 in Review

Morgan Stanley opened a new position in ProMIS Neurosciences (PMN) in Q2 2026: 7,559 shares worth $99.5K. The stake represents ﹤0.01% of the portfolio and ranks #6256 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in PMN as recently as Q2 2023.

Morgan Stanley first reported a position in PMN in Q3 2022 and has held it in 5 quarters since. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • Morgan Stanley held 7,559 shares of ProMIS Neurosciences worth $99.5K as of Q2 2026.
  • ProMIS Neurosciences was a new Morgan Stanley position in Q2 2026.
  • ProMIS Neurosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6256 holding.
  • Morgan Stanley first reported a position in ProMIS Neurosciences in Q3 2022 and has held it in 5 quarters since.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.